CJC-1295 UK: Complete Research Guide (2026)

CJC-1295 UK: Complete Research Guide (2026)

Research Disclaimer: CJC-1295 is sold for research and laboratory purposes only. It is not approved for human consumption and should not be used outside of controlled research settings. All information presented here is for educational purposes only.

What is CJC-1295?

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), a naturally occurring peptide hormone that regulates the synthesis and secretion of growth hormone from the anterior pituitary gland. As a GHRH analogue, CJC-1295 directly stimulates GHRH receptors in the pituitary, triggering the release of GH into circulation. The compound was developed through peptide engineering to improve upon the pharmacokinetic properties of native GHRH, which has a very short half-life and limited duration of action.

CJC-1295 is a 30-amino acid peptide that retains the critical GHRH-receptor-binding domain of native GHRH whilst incorporating structural modifications that enhance its stability and extend its biological activity. These modifications make CJC-1295 a valuable research tool for investigating GH physiology, metabolic regulation, and the long-term effects of enhanced GH signalling. The compound exists in two primary variants: CJC-1295 with DAC and CJC-1295 without DAC, each with distinct pharmacokinetic profiles and research applications.

Mechanism of Action: GHRH Analogue Function

CJC-1295 operates through direct activation of GHRH receptors located on somatotroph cells in the anterior pituitary gland. The GHRH receptor is a G-protein-coupled receptor (GPCR) that, when activated, triggers intracellular signalling cascades leading to the synthesis and secretion of growth hormone. Unlike growth hormone secretagogues such as Ipamorelin, which work through the ghrelin receptor (GHS-R1a), CJC-1295 works through a distinct GHRH receptor pathway.

The biological significance of this mechanism is that CJC-1295 stimulates GH release through the same receptor system that native GHRH activates, making it highly physiologically relevant for research purposes. The GHRH receptor pathway is one of the two primary positive regulators of GH secretion (the other being the ghrelin pathway), and research with CJC-1295 allows investigators to study the specific role of GHRH signalling in GH physiology without the confounding effects of other hormonal systems.

The duration and magnitude of GH secretion stimulated by CJC-1295 depend on several factors, including the dose administered, the frequency of dosing, and whether the CJC-1295 variant includes a DAC (drug affinity complex) moiety. These variables allow researchers to design protocols that produce different GH secretion profiles, from acute GH pulses to sustained elevation of GH and IGF-1.

CJC-1295 with DAC vs Without DAC: Pharmacokinetic Differences

The two primary variants of CJC-1295 differ fundamentally in their pharmacokinetics and duration of action, making them suitable for different research applications.

CJC-1295 with DAC (Drug Affinity Complex): The DAC is a carrier moiety composed of collagen-binding domain sequences that extend the half-life of CJC-1295 dramatically. In research settings, CJC-1295 with DAC exhibits a circulating half-life of approximately 7-8 days, compared to the much shorter half-life of unmodified CJC-1295. This extended half-life is achieved because the DAC facilitates binding of CJC-1295 to serum albumin and other blood proteins, reducing renal clearance and extending the duration of the compound in circulation.

The practical research advantage of CJC-1295 with DAC is that it can be administered less frequently — typically once every 5-7 days — whilst maintaining relatively stable circulating levels of the compound and consistent GH stimulation. This makes it valuable for long-term research studies where frequent dosing would be impractical or where investigation of sustained GH elevation is the research objective.

CJC-1295 without DAC: The non-DAC variant of CJC-1295 has a significantly shorter half-life, approximately 30-60 minutes, similar to the half-life of modified GRH-releasing hormones. This shorter duration means that CJC-1295 without DAC produces acute, brief pulses of GH secretion following administration. Research using this variant typically involves more frequent dosing — often multiple times daily — to achieve desired GH elevation profiles.

The research advantage of CJC-1295 without DAC is that it allows investigators to study the acute effects of GHRH stimulation and to produce distinct GH pulses that more closely mimic the natural pulsatile pattern of GH secretion. Additionally, the shorter duration of action allows for more precise temporal control over GH stimulation in experimental protocols.

From a research design perspective, the choice between CJC-1295 with DAC and without DAC depends on whether the study objective is to investigate sustained GH elevation (favouring the DAC variant) or acute pulsatile GH secretion (favouring the non-DAC variant).

GH and IGF-1 Elevation: Research Findings

Research examining CJC-1295’s effects on circulating GH and insulin-like growth factor 1 (IGF-1) has documented substantial elevations of both hormones following compound administration. The magnitude and duration of these elevations depend on the CJC-1295 variant used and the dosing protocol employed.

Studies using CJC-1295 with DAC have demonstrated sustained elevations of both GH and IGF-1 over days following a single injection. Research indicates that plasma GH concentrations may increase 2-5 fold above baseline, with peak elevations occurring within hours of injection. IGF-1, which is produced in the liver in response to elevated GH, shows more gradual increases over the course of days, with peak concentrations potentially doubling or tripling baseline values in some research protocols.

The elevation of IGF-1 is particularly relevant to research examining the metabolic and compositional effects of enhanced GH signalling, as many of the growth-promoting and metabolic effects of GH are mediated through IGF-1. Research has documented that the sustained elevation of IGF-1 produced by CJC-1295 administration is associated with numerous downstream metabolic changes relevant to body composition, protein synthesis, and metabolic rate.

In research using CJC-1295 without DAC, GH elevation is more transient, with acute increases in GH concentration following administration but with a return to baseline within hours. This acute elevation pattern allows researchers to study the immediate effects of GHRH stimulation on GH secretion and to investigate whether repeated acute pulses of GH produce cumulative metabolic effects.

Body Composition and Fat Loss: Research Studies

A substantial body of research has examined the effects of CJC-1295 administration on body composition, specifically investigating changes in lean body mass, adipose tissue distribution, and overall fat loss. These studies have been motivated by the understanding that growth hormone has significant effects on substrate partitioning, lipolysis, and protein synthesis.

Research in animal models has demonstrated that chronic CJC-1295 administration leads to measurable increases in lean body mass alongside reductions in total body fat and visceral adipose tissue. Studies have indicated that CJC-1295 may preferentially reduce visceral fat (abdominal adipose tissue that is metabolically active and associated with metabolic dysfunction), whilst preserving or even increasing lean mass.

The mechanisms underlying these compositional changes are multifactorial. GH promotes lipolysis (fat breakdown) through activation of hormone-sensitive lipase in adipocytes, increases metabolic rate through effects on mitochondrial function, and promotes protein synthesis in muscle tissue. Additionally, elevated IGF-1 (a consequence of elevated GH) stimulates glucose uptake and utilisation in muscle whilst promoting anabolic processes.

Research examining CJC-1295 in the context of age-related metabolic decline has indicated that the compound may ameliorate age-associated increases in adiposity and losses of lean mass. Studies in ageing animal models have shown that CJC-1295 administration can reverse some of the compositional changes associated with age, suggesting potential applications in understanding GH’s role in age-related metabolic dysfunction.

The timescale for observing compositional changes with CJC-1295 is typically several weeks to months, reflecting the gradual nature of body composition remodelling in response to enhanced GH signalling. Some research protocols have employed CJC-1295 for periods of 12 weeks or longer to achieve maximal compositional changes.

CJC-1295 and Ipamorelin Stack Research

One of the most extensively researched applications of CJC-1295 is its use in combination with Ipamorelin, a selective growth hormone secretagogue with a distinct mechanism of action. The rationale for combining these two compounds is grounded in endocrine physiology: GH secretion is regulated by two primary opposing pathways — positive regulation through GHRH (and ghrelin signalling) and negative regulation through somatostatin.

CJC-1295 stimulates GH release through the GHRH pathway, whilst Ipamorelin stimulates GH release through the ghrelin pathway. Research indicates that these two pathways are at least partially independent, meaning that combined stimulation through both pathways produces synergistic GH secretion — i.e., the combined effect is greater than the sum of the individual effects.

Studies examining CJC-1295 + Ipamorelin combinations have documented substantial increases in GH and IGF-1 concentrations, often exceeding the elevations produced by either compound administered alone. Research protocols using this combination have reported GH peak concentrations that are 2-3 times higher than baseline, with sustained elevation of IGF-1 over the dosing interval.

From a research design perspective, the CJC-1295 + Ipamorelin stack is valuable because it allows investigation of the effects of maximal (or near-maximal) GH stimulation on various research endpoints — body composition, metabolic parameters, recovery markers, and functional outcomes. The combination is also useful for research aimed at determining whether additive GH stimulation produces proportionally greater effects on specific outcomes than single-pathway stimulation.

Typical protocols combine CJC-1295 (either variant) with daily or twice-daily Ipamorelin injections. The specific dosing schedule depends on research objectives and whether the study is designed to produce acute GH pulses or sustained GH elevation.

Dosing Protocols from Research

CJC-1295 dosing protocols in research vary based on whether the DAC variant or non-DAC variant is being used and on the specific research objectives of the study.

CJC-1295 with DAC: Research protocols typically employ doses of 1-2 milligrams per injection, administered once every 5-7 days. Some studies have used lower doses (500 micrograms) or higher doses (2-3 mg) depending on the desired magnitude of GH elevation. The extended half-life of the DAC variant means that frequent dosing is not necessary; indeed, protocols using weekly dosing have become standard in research applications.

CJC-1295 without DAC: The non-DAC variant is typically administered more frequently, often 1-2 times daily, with per-injection doses of 100-300 micrograms depending on the desired magnitude of GH stimulation. Some research protocols employ split dosing to achieve a more consistent elevation of circulating GH throughout the day.

Combined CJC-1295 + Ipamorelin protocols: When these compounds are combined, CJC-1295 dosing remains as above (1-2 mg weekly for the DAC variant, or 100-300 micrograms daily for the non-DAC variant), whilst Ipamorelin is typically administered at 100-300 micrograms daily or twice daily. Some research protocols use evening-only dosing to capitalise on the natural GH surge associated with sleep.

Timing considerations are relevant to research objectives. Many protocols administer compounds in the evening to synchronise with the natural circadian rhythm of GH secretion, potentially creating more physiologically relevant GH elevation profiles.

Safety Profile in Research

Research examining CJC-1295’s safety profile in animal models has indicated generally favourable tolerability at research-grade dosing. The compound does not appear to elicit significant hepatic or renal toxicity, and clinical laboratory parameters (liver enzymes, kidney function markers) remain within normal ranges in most research protocols.

Notably, CJC-1295 operates through the native GHRH receptor, which is the physiological pathway for GH regulation, suggesting that the compound works through endogenous regulatory mechanisms. This may contribute to a more favourable safety profile compared to non-selective compounds or exogenous GH administration, which can suppress endogenous GH secretion through negative feedback.

However, chronic administration of CJC-1295 — like other GH-stimulating compounds — may lead to tachyphylaxis (reduced response to repeated dosing). Research has indicated that periodic dosing breaks may be beneficial for maintaining responsiveness in long-term studies. Additionally, elevated GH and IGF-1 over extended periods may carry theoretical risks related to cell proliferation, though research in this area remains ongoing.

Local injection site reactions are possible with peptide compounds, and standard laboratory practice (aseptic technique, rotating injection sites) minimises these effects. The purity and quality of the compound are critical determinants of safety, reinforcing the importance of sourcing CJC-1295 from reputable, quality-controlled suppliers.

Storage and Reconstitution Guidelines

CJC-1295 is supplied as a lyophilised powder requiring reconstitution prior to use. Proper storage of both the unreconstituted powder and reconstituted solution is essential for maintaining compound integrity and efficacy.

Unreconstituted powder storage: The lyophilised CJC-1295 vial should be stored at 2-8°C (refrigerated), away from light and moisture. The powder should maintain stability for extended periods under these conditions, typically 1-2 years or longer depending on storage conditions and the supplier’s specifications.

Reconstitution procedure: CJC-1295 is reconstituted using bacteriostatic water or physiological saline (0.9% sodium chloride). The reconstitution process should be performed aseptically using sterile technique. The vial should be inverted gently multiple times to facilitate dissolution, rather than shaken vigorously. The gentle approach prevents foaming and potential peptide aggregation.

Reconstituted solution storage: Once reconstituted, CJC-1295 solutions should be stored at 2-8°C and should be used within a defined timeframe, typically 2-4 weeks, though exact stability depends on the specific diluent used and storage conditions. Some researchers store reconstituted solutions as frozen aliquots to extend shelf-life, though repeated freeze-thaw cycling may compromise stability.

Administration is via subcutaneous injection using sterile syringes and needles. Rotation of injection sites minimises local tissue reactions, and all equipment should be sterilised according to standard laboratory protocols.

UK Legal Status

CJC-1295 is not approved as a pharmaceutical medication in the United Kingdom. It is classified as a research chemical and is legally available for purchase through licensed research suppliers for legitimate research and laboratory purposes. The compound is not controlled under the Misuse of Drugs Act, though it is subject to regulations governing research chemicals and peptides.

All suppliers in the UK must ensure that CJC-1295 is sold with appropriate labelling stating its research-only status and explicitly indicating that it is not approved for human consumption. Researchers and institutions must purchase CJC-1295 through reputable, licensed suppliers and maintain proper documentation of its use for research purposes.

UK Sourcing and Quality Standards

When sourcing CJC-1295 in the United Kingdom, researchers should prioritise suppliers who maintain rigorous quality assurance protocols and provide comprehensive documentation. Reputable UK suppliers provide certificates of analysis (COA) from independent third-party laboratories confirming purity, identity, and potency of the supplied compound.

Quality indicators to evaluate include: third-party laboratory verification of purity and amino acid sequence accuracy, documentation of manufacturer identity and GMP (Good Manufacturing Practice) certification, proper storage and handling conditions, and transparent pricing. Establishing relationships with trusted UK-based suppliers ensures consistent product quality and regulatory compliance across research projects.

Frequently Asked Questions

1. What is the difference between CJC-1295 with DAC and CJC-1295 without DAC?
CJC-1295 with DAC has an extended half-life (7-8 days) due to the drug affinity complex, allowing weekly dosing. CJC-1295 without DAC has a much shorter half-life (30-60 minutes) requiring more frequent dosing. The choice depends on research objectives — sustained GH elevation vs acute pulses.

2. How long does it take to observe changes in body composition with CJC-1295?
Body composition changes typically become apparent over 8-12 weeks or longer of continuous administration. Gradual remodelling of lean mass and adipose tissue develops over weeks as a consequence of sustained elevated GH and IGF-1.

3. Can CJC-1295 be mixed with other research compounds in the same syringe?
Yes, CJC-1295 is frequently combined with Ipamorelin or other peptide compounds. Many research protocols involve concurrent administration of multiple peptides to produce synergistic effects. Proper dosing and protocol design are essential when combining compounds.

4. What is the timeline for IGF-1 elevation with CJC-1295?
With CJC-1295 with DAC, IGF-1 elevation becomes apparent within days and peaks over 5-7 days following injection. With CJC-1295 without DAC, IGF-1 elevation is more gradual, as acute GH pulses must accumulate to produce sustained IGF-1 elevation.

5. Does CJC-1295 suppress natural GH production?
Research suggests that CJC-1295 works through the native GHRH pathway, which may minimise suppression of endogenous GH production compared to exogenous GH administration. However, very high doses or prolonged administration may suppress endogenous GHRH production through negative feedback.

6. Is CJC-1295 stable at room temperature?
No. CJC-1295 as a lyophilised powder must be stored refrigerated (2-8°C) to maintain stability. Reconstituted solutions are also temperature-sensitive and should be refrigerated. Exposure to elevated temperatures will degrade the compound.

7. How does CJC-1295 compare to native GHRH?
CJC-1295 is a synthetic GHRH analogue with structural modifications that extend its half-life far beyond native GHRH (which has a half-life of minutes). This extended stability makes CJC-1295 more practical for research and allows for less frequent dosing.

8. What is the significance of the amino acid sequence in CJC-1295?
The 30-amino acid sequence of CJC-1295 includes the critical GHRH-receptor-binding domain, ensuring that the compound activates GHRH receptors appropriately. Modifications to the sequence stabilise the peptide against degradation whilst preserving receptor binding.

9. Are there dose-response relationships with CJC-1295?
Yes, research indicates dose-dependent effects on GH and IGF-1 elevation. Higher doses produce greater GH secretion up to a saturation point, beyond which further dose increases may not produce proportional increases in GH release.

10. Can CJC-1295 be used to study seasonal or diurnal variations in GH secretion?
Yes, research has used CJC-1295 to investigate whether controlled GHRH stimulation produces different GH responses depending on time of day or seasonal factors. Such studies have relevance to understanding circadian and seasonal regulation of GH physiology.